Uni-Bio Science Group Limited, an investment holding company, researches and develops, manufactures, and sells biological and chemical pharmaceutical products to treat human diseases in the People’s Republic of China. It operates through Chemical Pharmaceutical Products, Biological Pharmaceutical Products, and Pipeline Products segments. The company provides BOGUTAI, a disposable injection pen for the treatment of osteoporosis; GeneTime, a prescription biological drug for wound healing; GeneSoft, a therapeutic drug for dry eye syndrome, corneal damage, and post-operative healing; Pinup, a voriconazole tablet to treat invasive aspergillosis and fungal infections; and Boshutai, an oral medication for the treatment of diabetes. It also develops prescription drugs, such as UOS003(oral PTH) for the treatment of osteoporosis; Uni-GLP-1, a non-insulin treatment candidate that stimulates the incretin pathway for the treatment of type 2 diabetes and obesity; and pre-clinical stage biopharmaceutical products for wound care and ophthalmology. In addition, the company offers contract manufacture organization services. Uni-Bio Science Group Limited was incorporated in 2001 and is headquartered in Sha Tin, Hong Kong.